BVES: A Potential Drug Target for Cardiovascular Disease (G11149)

Target Name: BVES

NCBI ID: G11149

BVES

BVES: A Potential Drug Target for Cardiovascular Disease

Blood Vessel Epicardial Substance (BVES) is a protein that is expressed in the blood vessels and in the intercellular matrix surrounding them. It is a unique protein that has been identified as a potential drug target in the field of cardiovascular disease.

The BVES protein is involved in the regulation of cell signaling pathways that are important for maintaining cardiovascular health. It has been shown to play a role in the development and progression of various cardiovascular conditions, including heart failure, hypertension, and diabetes.

One of the key functions of BVES is its role in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. BVES has been shown to play a key role in the production and maintenance of endothelial cells, which are the cells that line the blood vessels.

In addition to its role in angiogenesis, BVES is also involved in the regulation of cell signaling pathways that are important for maintaining cardiovascular health. It has been shown to play a role in the regulation of signaling pathways that are important for blood pressure, heart rate, and cholesterol levels.

Despite the potential benefits of BVES as a drug target, much more research is needed before a clinical trial can be conducted to test its effectiveness. Currently, there are no approved drugs that are specifically targeting BVES.

However, research into BVES is ongoing, and it is an exciting time for the field of cardiovascular disease. As more research is conducted, it is likely that new treatments will be developed that are specifically targeted to BVES.

In conclusion, BVES is a protein that has the potential to be a drug target in the field of cardiovascular disease. Further research is needed to understand its full role in the regulation of cardiovascular health and to develop effective treatments that are specifically targeted to it.

Protein Name: Blood Vessel Epicardial Substance

Functions: Cell adhesion molecule involved in the establishment and/or maintenance of cell integrity. Involved in the formation and regulation of the tight junction (TJ) paracellular permeability barrier in epithelial cells (PubMed:16188940). Plays a role in VAMP3-mediated vesicular transport and recycling of different receptor molecules through its interaction with VAMP3. Plays a role in the regulation of cell shape and movement by modulating the Rho-family GTPase activity through its interaction with ARHGEF25/GEFT. Induces primordial adhesive contact and aggregation of epithelial cells in a Ca(2+)-independent manner. Also involved in striated muscle regeneration and repair and in the regulation of cell spreading (By similarity). Important for the maintenance of cardiac function. Plays a regulatory function in heart rate dynamics mediated, at least in part, through cAMP-binding and, probably, by increasing cell surface expression of the potassium channel KCNK2 and enhancing current density (PubMed:26642364). Is also a caveolae-associated protein important for the preservation of caveolae structural and functional integrity as well as for heart protection against ischemia injury

The "BVES Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BVES comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets